Project organization: MilliporeSigma/EMD Serono

Use of Metabolic Flux Analysis (MFA) to Expedite Media Selection and Optimization of CHO

Optimizing Next Generation Sequencing for Sensitive Detection of Viral Adventitious Agents in Biologics

Commercial Deployment of Integrated PAT Technologies to Enable Continuous Upstream Production of Glycosylated Monoclonal Antibodies

Next-generation Factory Business & Data Mapping

Discover Negotiate Pair (DNP) Development

Surrogate ADCs for Process Development and Quality Assessment

Next Gen High Level Design of Facility Layout

Innovative scalable technologies for production of cell therapies

Protein A Chromatography Multi-scale Data Driven/Mechanistic Modeling (Phase 2)

Cell Culture Glycosylation Multi-scale Data Driven Mechanistic Modeling (Phase 2)

N-mAb

Buffer Stock Blending System